Accelerated nodulosis and vasculitis during methotrexate therapy for rheumatoid arthritis
Open Access
- 1 September 1988
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 31 (9) , 1182-1185
- https://doi.org/10.1002/art.1780310915
Abstract
Three women with classic rheumatoid arthritis, who were receiving weekly doses of methotrexate (MTX), developed accelerated subcutaneous nodulosis, despite good response to the drug. In 2 of the patients, the onset of nodulosis occurred within 3 months and 5 months, respectively, after starting MTX; in the third patient, it was observed only after 4 years of MTX therapy. In all 3 patients, the onset was unusually abrupt, with extensive distribution and remarkable nodule size. Additional manifestations of cutaneous vasculitis in 2 of the patients and Raynaud's phenomenon in the third appeared concomitantly with the nodulosis. Physicians prescribing MTX therapy for patients with rheumatoid arthritis should be aware of these potential complications.This publication has 7 references indexed in Scilit:
- Immunologic studies of rheumatoid arthritis patients treated with methotrexateArthritis & Rheumatism, 1987
- The safety and efficacy of the use of methotrexate in long‐term therapy for rheumatoid arthritisArthritis & Rheumatism, 1986
- Immunogenetics of rheumatoid arthritis in IsraelTissue Antigens, 1986
- MEASURES OF IMMUNOLOGICAL AND INFLAMMATORY RESPONSES INVITRO IN RHEUMATOID PATIENTS TREATED WITH METHOTREXATE1986
- Weekly Pulse Methotrexate in Rheumatoid ArthritisAnnals of Internal Medicine, 1985
- Rheumatoid nodulesThe American Journal of Medicine, 1984
- Antinuclear factor in rheumatoid arthritis and related diseases.Annals of the Rheumatic Diseases, 1967